DNA Methylation and Autoimmune Thyroid Diseases

Plain-language summary

This is an observational study investigating the relationship between DNA methylation and autoimmune thyroid diseases. It included children and adolescents with Hashimoto's thyroiditis or Graves' disease along with matched healthy controls. It was conducted as a non-phase observational study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Aristotle University Of Thessaloniki

Start date

9/1/2014

Estimated completion

4/1/2018

Countries

Greece

Related genes

Locations

• Thessaloniki, Greece

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

For HT:

A positive titers of antithyroid peroxidase (anti-TPO) or antithyroglobulin (anti-Tg) antibodies and at least one of:

* Abnormal thyroid function that requires substitution treatment with L-thyroxine (TSH \> 5 μIU/ml and decreased or normal levels of fT4 or fT3)
* Increased volume of thyroid gland (goiter)
* Morphological changes on ultrasound of the thyroid gland

For GD:

* A positive titers of thyroid stimulating antibodies (anti-TSI) and
* Decreased TSH levels and increased levels of fT4 or fT3

For Controls:

* Otherwise healthy children and adolescents, age- and gender-matched with patients
* Absence of previously known chronic disease of autoimmune aetiology or atopy (including those with a history of chronic treatment with antihistamines, anti-inflammatory, corticosteroids or anti-epileptic drugs)
* Absence of a family history of autoimmune disease in first-degree relatives

Exclusion Criteria:

* Not Caucasian origin or affinity among participants
* Age of diagnosis above 18 years
* Disease duration below 3 months